PDS Biotechnology Corp. Stock News

EMV Capital plc (AIM: EMVC) portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) has raised $11 million, through an equity funding. PDS, which is focussed on immunotherapies, sold around 7.33 million new shares in a direct offer, plus warrants which (if exercised) will bring in another $11 million.

PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced it has entered into securities purchase agreements with new and existing healthcare focused institutional investors as well as participation fr...

Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpoint inhibitor naïve patients - mOS not yet reached Median OS of 17 months in HPV16-positive immune checkpoint inhibitor resistant patients; Historically published result is 3-4 months Significant t...

Data confirms Versamune ® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025

PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat at the B.

PRINCETON, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that on December 3, 2024, PDS Biotech granted nonstatutory stock options to purchase 7,000 s...

Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation

PDS Biotechnology Corporation (NASDAQ:PDSB ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - Chief Executive Officer Lars Boesgaard - Chief Financial Officer Kirk Shepard - Chief Medical Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Ali Rashidfarrokhi - B. Riley Robert LeBoyer - Noble Capi...